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TheMSH6 gene is one of the mismatch-repair genes involved in hereditary nonpolyposis colorectal cancer (HNPCC).
Three hundred sixteen individuals who were known or suspected to have HNPCCwere analyzed forMSH6 germline
mutations. For 25 index patients and 8 relatives withMSH6 variants, molecular and clinical features are described.
For analysis of microsatellite instability (MSI), the five consensus markers were used. Immunohistochemical analysis
of the MLH1, MSH2, and MSH6 proteins was performed. Five truncating MSH6 mutations, of which one was
detected seven times, were found in 12 index patients, and 10 MSH6 variants with unknown pathogenicity were
found in 13 index patients. Fourteen (54%) of 26 colorectal cancers (CRCs) and endometrial cancers showed no,
or only weak, MSI. Twelve of 18 tumors of truncating-mutation carriers and 3 of 17 tumors of missense-mutation
carriers showed loss of MSH6 staining. Six of the families that we studied fulfilled the original Amsterdam criteria;
most families withMSH6, however, were only suspected to have HNPCC. In families that did not fulfill the revised
Amsterdam criteria, the prevalence ofMSH6 variants is about the same as the prevalence of those inMLH1/MSH2.
Endometrial cancer and/or atypical hyperplasia were diagnosed in 8 of 12 female carriers of MSH6 truncating
mutations. Most CRCs were localized distally in the colon. Although, molecularly, missense variants are labeled
as doubtfully pathogenic, clinical data disclose a great resemblance betweenmissense-variant carriers and truncating-
mutation carriers. We conclude that, in all patients suspected to have HNPCC, MSH6-mutation analysis should
be considered. Neither MSI nor immunohistochemistry should be a definitive selection criterion forMSH6-mutation
analysis.
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC
[MIM 114400; MIM 114500]) is an autosomal domi-
nant disorder, characterized by the early onset of gas-
trointestinal and urogenital cancers—in particular, co-
lorectal cancer (CRC) and endometrial cancer. Germline
mutations in four mismatch-repair (MMR) genes have
thus far been associated with HNPCC: MLH1, MSH2,
MSH6, and PMS2. Most of these mutations have been
detected in MLH1 and MSH2. The loss of MMR
function—particularly, when due to MLH1 and MSH2
mutations—leads to somatic DNA replication errors in
repetitive sequences, known as “microsatellites” (Aal-
tonen et al. 1993). Microsatellite instability (MSI), there-
fore, is the hallmark of the majority of cancers associated
Received July 31, 2001; accepted for publication October 8, 2001;
electronically published November 13, 2001.
Address for correspondence and reprints: Dr. J. H. Kleibeuker,
Department of Gastroenterology, University Hospital of Groningen,
P.O. Box 30.001, 9700 RB Groningen, The Netherlands. E-mail:
J.H.Kleibeuker@int.azg.nl
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7001-0005$15.00
with HNPCC. In MLH1- and MSH2-mutation carriers,
MSI has been found in 190% of CRCs and in 175% of
endometrial cancers (Aaltonen et al. 1993; Peltoma¨ki et
al. 1993; Kowalski et al. 1997).
In 1995, Drummond et al. (1995), Palombo et al.
(1995), and Papadopoulos et al. (1995) reported the
identification of a gene that is now referred to as
“MSH6” (MIM 600678). Whereas MSH2 in combi-
nation with MSH6 is involved in repair of single-nu-
cleotide mismatches, MSH2 in combination withMSH3
is mainly involved in the repair of small insertions and
deletions (Drummond et al. 1995; Palombo et al. 1995;
Acharya et al. 1996; Marsischky et al. 1996). The first
reports of human MSH6 germline mutations were by
Akiyama et al. (1997) and Miyaki et al. (1997). They
described MSH6 germline mutations in members of two
families that did not fulfill the Amsterdam (I) criteria
for HNPCC (Vasen et al. 1991). When looking for
MSH6 mutations in families fulfilling those criteria (i.e.,
typical families with HNPCC), most investigators did
not find any such mutations (Papadopoulos et al. 1995;
Liu et al. 1996; Akiyama et al. 1997; Kolodner et al.
1999; Wang et al. 1999). However, Wijnen et al. (1999)
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and Wu et al. (1999) reported the occurrence of MSH6
germline mutations in a small, though significant, frac-
tion of families that fulfilled the revised Amsterdam cri-
teria (Vasen et al. 1999). An explanation for the lower
frequency of MSH6 mutations in such families with
HNPCC may be that the loss of MSH6 function causes
only a partial MMR defect, so that the penetrance of
the genetic predisposition may be lower than it is in the
case of mutations in either MLH1 or MSH2. Further-
more, Wu et al. (1999) showed that most of the patients
who carried an MSH6 mutation had tumors displaying
an MSI-low (MSI-L) phenotype. Until now, however,
MMR-gene–mutation analysis has been performed pre-
dominantly in patients with MSI-high (MSI-H) tumors.
This may also explain the small numbers of MSH6 mu-
tations found.
Most of the MSH6 germline mutations that have thus
far been described occur in families that are only sus-
pected to have HNPCC (Kolodner et al. 1999; Shin et
al. 1999; Verma et al. 1999; Wijnen et al. 1999; Wu et
al. 1999; Planck et al. 1999). In addition, current data
suggest that the age at onset of CRC and of endometrial
cancer is higher in MSH6-germline-mutation carriers
than in the families with MLH1 or MSH2 germline
mutations and that these kindreds display a high fre-
quency of endometrial cancer or atypical endometrial
hyperplasia (Miyaki et al. 1997; Wijnen et al. 1999;
Wagner et al. 2001).
The aim of the present study is to describe the mo-
lecular and clinical findings in all carriers of germline
MSH6 variants whom we have detected up to January
2001, to further define the molecular and clinical im-
plications of MSH6 germline variants.
Subjects and Methods
Patient Population
Patients, who were analyzed for germline mutations
in MSH6, were retrieved from two sources. The first
source comprised the patients included in a study of the
role that MMR-gene mutations played in individuals
who were suspected to have HNPCC. Two hundred six
patients were referred, for this study, by hospital doctors
and general practitioners in the north of the Netherlands.
All of the patients referred fulfilled one of the four in-
clusion criteria, which are given in Appendix A. Infor-
mation about the family history (up to and including
the third-degree relatives) was collected, and blood sam-
ples were taken from those patients who gave informed
consent after written and verbal pretest counseling. For-
malin-fixed paraffin-embedded tumor material was ob-
tained and was revised. With the permission of the in-
dividuals involved, medical records of affected family
members were collected, if possible, to verify the nature
of reported tumors. The institutional review boards of
the University Hospital Groningen and other partici-
pating hospitals approved the study. The participating
patients were informed of the results of the genetic test,
if they wished to be; in that case, they received verbal
posttest counseling and a written summary.
The second source comprised 110 patients referred to
the Department of Medical Genetics of the University
Hospital Groningen because of suspicion of hereditary
CRC. Half of the patients in this group fulfilled one of
the criteria mentioned in Appendix A; those who did
not were of more advanced age at diagnosis or were
referred from other genetic departments in the absence
of sufficient information about their families. In the di-
agnostic setting, patients with MSI-L tumors were an-
alyzed for MSH6 mutations, as were the patients with
MSI-H tumors but without detected germline mutations
in MLH1 or MSH2.
Mutation Analysis
Mutation analysis of theMSH6 gene in DNA obtained
from peripheral blood lymphocytes was performed by
denaturing gradient-gel electrophoresis. Variants were
confirmed by direct sequencing of independently am-
plified PCR products, as described elsewhere (Wu et al.
1997, 1999). Sequencing was performed with an ABI
PRISM 377 DNA sequencer (PE Biosystems). In almost
all patients, the MLH1 and MSH2 genes were analyzed
as well. Mutations in these genes are reported here only
when occurring concurrent with an MSH6 variant. No
search for germline genomic deletions was performed.
Two hundred unaffected Dutch individuals served as a
control group.
MSI Analysis
MSI primers were used in the manner proposed at the
international workshop on HNPCC, in Bethesda (Bo-
land et al. 1998). These include two mononucleotide
repeats (BAT25 and BAT26) and three dinucleotide re-
peats (D2S123, D5S346, and D17S250). Another mono-
nucleotide marker (BAT40) was also used in all patients,
since MSI in MSH6 carriers has been mainly observed
at mononucleotide markers (Verma et al. 1999; Wijnen
et al. 1999). DNA was extracted from formalin-fixed
paraffin-embedded tumor sections. Control DNA was
obtained either from normal tissue from paraffin-em-
bedded sections or from peripheral blood of the same
patients. PCR products were analyzed in 6% denaturing
polyacrylamide gels on an LKB. A.L.F. DNA sequencer
(Pharmacia). For data analysis, the DNA fragment an-
alyzer (Pharmacia) was used. Tumors were classified as
MSI-H when two or more of the five consensus markers
showed MSI and as MSI-L when zero or one of the
markers showed MSI. Since a limited number of markers
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were analyzed, the classification “MSI stable” will not
be used.
Immunohistochemistry
For MSH6, MLH1, and MSH2 immunohistochem-
istry, formalin-fixed paraffin-embedded tissue sections
were collected from the proved carriers of MSH6 vari-
ants. Three-micrometer sections of deparaffinized tumor
tissue were mounted on slides with APES coating (3-
aminopropyl triethoxysilan; Sigma-Aldrich). Antigen re-
trieval was performed by autoclave heating. The slides
were incubated with mouse monoclonal antibodies to
MSH6 (1:200) (clone 44; BD Transduction Laborato-
ries), to MLH1 (1:500) (clone G168-728; PharMingen),
or to MSH2 (1:100) (Ab-2; Calbiochem). The slides
were successively treated with rabbit–anti-mouse per-
oxidase and with goat–anti-rabbit peroxidase. The chro-
mogen was diaminobenzidine, and counterstaining was
performed with hematoxylin. Protein expression in nor-
mal tissue next to the tumor served as internal positive
control. The sections were scored as either negative (i.e.,
in the absence of detectable nuclear staining of tumor
cells) or positive for MSH6, MLH1, and MSH2 ex-
pression. Scoring of the tumor staining was performed
without knowledge of the MSI or of mutation status.
Results
Patient Population
A total of 316 apparently unrelated patients were an-
alyzed for MSH6 mutations. Of these 316 patients, 261
(106 men and 155 women) met the inclusion criteria,
which are given in Appendix A. When dividing these
patients according to the four criteria, 187 patients, of
which 149 had CRC and 38 had endometrial cancer
diagnosed at the age of !50 years, fulfilled criterion 1.
Twelve patients either had an HNPCC-related tumor
and a first-degree relative with CRC or endometrial can-
cer, one of which was diagnosed at the age of !50 years,
or had CRC or endometrial cancer and a first-degree
relative with an HNPCC-related tumor, one of which
was diagnosed at the age of !50 years; 54 patients had
multiple HNPCC-related tumors; and 8 patients had a
colorectal adenoma.
Mutation Analysis
In 23 of the 261 patients, MSH6 germline variants
were found. These include five variants that have been
reported elsewhere (Wu et al. 1999). Twenty-seven of
the 261 patients belonged to families with HNPCC that
was considered to be established, by fulfillment of the
original Amsterdam criteria (Vasen et al. 1991), but
without germline mutations in MLH1 and MSH2. Four
of these 27 patients had an MSH6 variant. An additional
55 patients analyzed in the diagnostic setting did not
fulfill the inclusion criteria. In two of these patients, an
MSH6 germline variant was found, bringing the total
number of index carriers of an MSH6 germline variant
to 25.
The variants observed included five different truncat-
ing mutations that occurred in 12 index patients (group
A; table 1). Seven patients shared the same truncating
mutation in exon 4a. Haplotype analysis with four in-
tragenic single-nucleotide polymorphisms, located in ex-
ons 2–4 and 7 of the MSH6 gene, indicated a founder
effect (data not shown). The remaining 10 variants, oc-
curring in 13 index patients (group B), were missense
variants (table 1). None of these variants was observed
in the 200 control individuals. Six of these variants re-
sulted in substitution of amino acids belonging to dif-
ferent polarity groups, whereas the other four variants
resulted in substitution of amino acids belonging to the
same polarity group (table 1). One of the missense var-
iants was found in a patient who also carries an MLH1
truncating mutation. This individual (patient 15) was
therefore excluded from group calculations. Another 10
sequence variations of MSH6 were found in six different
exons and have been reported as polymorphisms to the
International Collaborative Group on Hereditary Non-
polyposis Colorectal Cancer database. The allele fre-
quencies varied from 49.7% to 0.3% in the Dutch
population.
MSI Analysis
Various types of tumor material were available from
the 25 index patients and the 8 family members, all of
whom were known to carry an MSH6 variant. Tumor
material available for MSI analysis comprised 22 CRCs
and 6 endometrial cancers (tables 2 and 3); 2 transitional
cell cancers (1 of the renal pelvis and 1 of the bladder);
1 duodenal, 1 gastric, and 1 ovarian cancer; 3 colorectal
adenomas; and 1 endometrial hyperplasia. After patient
15 was excluded, 14 (54%) of the remaining 26 CRCs
and endometrial cancers were MSI-L. In group A (table
2), 5 of 13 CRCs and all 3 endometrial cancers (all of
which were from founder-mutation carriers) were MSI-
L. In group B (table 2), five of eight CRCs and one of
two endometrial cancers were MSI-L.
Immunohistochemistry
Immunohistochemical analysis of MLH1, MSH2, and
MSH6 was possible in 35 different tumors of theMSH6-
variant carriers, including, in this analysis, patient 15
(table 1). In group A, 12 (8 CRCs, 2 endometrial cancers,
1 renal pelvis cancer, and 1 duodenal cancer) of the 18
tumors showed clear absence of MSH6 staining; in 6
tumors (3 CRCs, 1 endometrial cancer, and 2 urothelial
cancers), MSH6 staining was present. In group B, 13 (8
Table 1
Molecular and Immunohistochemical Data—and MSI Results—for the Patients with MSH6 Mutations
PATIENT/FAMILY
MEMBERa [SEX] CANCERb [AGE (YEARS)] MUTATION(S)
POLARITY
DATAc MSId
IMMUNOHISTOCHEMICALe
MSH6 MLH1 MSH2
Truncating mutation
(group A):
1 [F] EC [46] 650insT L No Yes Yes
1 [F] CRC [37] 650insT L ND ND ND
2 [M] CRC-L [41] 650insT L No Yes Yes
3 [F] CRC-L [59], EC [65] 650insT L, L No, yes Yes, yes Yes, yes
4 [F] CRC-L [46] 650insT L Yes Yes Yes
5 [F] EC [50], CRC-R [50], CRC-L [83] 650insT ND, H ND, no ND, yes ND, yes
5 [F] EC [55] 650insT L No Yes No
5 [M] CRC-L [37] 650insT H No Yes Yes
6 [F] CRC-R [45], CRC-L [53], ST [62] 650insT ND, H, ND ND, failed, ND ND, failed, ND ND, failed, ND
7 [F] CRC-L [51], DUOD [51], CAH [51] 650insT ND, L, ND ND, no, ND ND, yes, ND ND, yes, ND
8 [M] CRC-R [38] 3263insT H Focal Yes Yes
9f [F] Pelvis [63], ureter [64], BC [65], CRC-L [77] Gln1258stop H, ND, L, L No, yes, yes, no Yes, yes, yes, yes Yes, yes, yes, yes
10 [M] CRC-R [55], CRC-L [55] 2672delT, 2674delT H, H Yes, no No, no Yes, yes
11 [M] CRC-R [47] 2672delT, 2674delT H No Yes No
12 [F] OC [35], CRC-R [54] Gln1280stop ND, H ND, no ND, yes ND, yes
Missense mutation
(group B):
13 [F] EC [45], CAH [45] Ser144Ile PrNP H, H Yes, yes Yes, yes Yes, yes
13 [F] CRC [49] Ser144Ile PrNP H No, no IC Yes No
14 [M] CRC-L [48] Ser144Ile PrNP L Yes Yes Yes
15g[F] EC [49], CRC-L [53] Tyr850Cys PrP H, H No, yes No, no Yes, yes
16 [M] CRC-L [63] Ala1021Asp NPrAP L Yes Yes Yes
17 [M] CRC-R [43] His1248Asp BPrAP L Yes Yes Yes
18 [F] CRC-R [37], CNAH [43] Thr1219Ile PrNP H, ND Yes, yes Yes, yes Yes, yes
19 [M] CRC-L [42] Thr1100Met PrNP L (AD) Yes Yes Yes
20 [F] CRC-R [36] Ile725Met NPrNP L Yes Yes Yes
21 [F] CRC-L [36] Gln522Arg PrBP L Yes Yes Yes
21 [F] CRC-L [40] Gln522Arg PrBP H Yes Yes Yes
22 [F] BRC [44], ST [64] Val878Ala NPrNP L Failed Failed Failed
23 [F] AD-R [53] Val878Ala NPrNP L ND Yes Yes
24 [F] CRC-L [45] Val878Ala NPrNP L (AD) Yes (AD) Yes Yes
25 [F] EC [46], OC [46] IVS1040ins10bp L, H No, ND Yes, yes Yes, yes
a Affected family members are indicated by the addition of “” or “” after the index patients’ number.
b CRCs are divided among left sided (CRC-L) and right sided (CRC-R); colorectal adenomas (ADs) are divided among left sided (AD-L) and right sided (AD-R). BL p bladder
cancer; BRC p breast cancer; CAH p complex atypical hyperplasia; CNAH p complex non-atypical hyperplasia; DUOD p duodenal cancer; EC p endometrial cancer; OC p
ovarian cancer; ST p stomach cancer.
c Amino acid substitutions: P p uncharged polar; NP p nonpolar; AP p acidic charged polar; BP p basic charged polar.
d L p MSI-L; H p MSI-H; ND p not done.
e ND p not done; no IC p no internal control.
f This patient had multiple tumors (namely: OC, at age 49 years; sigmoid, at age 55 years; EC, at age 57 years; right renal pelvis, at age 63 years; left ureter, at age 64 years;
BL, at age 65 years; basocellular, at age 75 years; ureter, at age 77 years; two rectal carcinomas, at age 77 years).
g This patient also had an MLH1 truncating mutation.
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Table 2
MSI Results, for CRC and Endometrial Cancer, in MSH6-Mutation
Carriers
PATIENT/
FAMILY
MEMBERa
MARKERb
MSIcBat25 Bat26 Bat40 D2S123 D5S346 D17S250
CRC-L:
1 … … … … … … L
2 … … … Yes … … L
3 … … Yes … … … L
4 … … … … … … L
5 Yes Yes Yes … Yes Yes H
5 Yes Yes ND … … Yes H
6 … Yes Yes Yes … Yes H
9 … … Yes … … … L
10 Yes Yes Yes Yes Yes Yes H
13 … ND … Yes Yes? Yes H
14 … Yes … … … … L
151 … … Yes ND … Yes H
16 … … … … … … L
21 … … … … … Yes L
21 Yes … … … … Yes H
CRC-R:
8 Yes Yes Yes … … Yes H
10 Yes Yes Yes Yes Yes Yes H
11 Yes Yes ND ND Yes Yes H
12 Yes Yes ND Yes … Yes H
17 … … … … … ND L
18 Yes Yes ND … Yes Yes H
20 ND … … … … … L
EC:
1 … … … … … … L
3 Yes … Yes … … … L
5 … … … … … … L
13 … … … Yes ND Yes H
15d … …  Loss Yes Yes Yes H
25 … … … … … Yes L
a CRCs are divided among left sided (CRC-L) and right sided (CRC-R); EC
p endometrial cancer. Patients/family members with a truncating mutation
are underlined; affected family members are indicated by the addition of “”
or “” after the index patients’ number.
b Yes p unstable marker; ND p not done.
c L p MSI-L; H p MSI-H.
d This patient also had an MLH1 truncating mutation.
Table 3
MSI Results for CRC and Endometrial Cancer
MUTATION
NO. OF CRCS
NO. OF
ENDOMETRIAL
CANCERS TOTAL
MSI-L MSI-H MSI-L MSI-H MSI-L MSI-H
Truncating 5 8 3 0 8 8
Missense 5 3 1 1 6 4
Total 10 11 4 1 14 12
NOTE.—The patient with the additional frameshift MLH1 mu-
tation was excluded.
CRCs, 1 endometrial cancer, 2 adenomas, and 2 endo-
metrial hyperplasias) of the 16 tumors showed MSH6
staining; in 2 endometrial cancers and 1 CRC, no stain-
ing was seen (in the latter, without a positive internal
control).
Clinical Data
In addition to the 25 index patients (17 female and 8
male), 8 affected family members—7 females and 1 male
(these family members are indicated in tables 1 and 2,
by the index patients’ number appended with either “”
or “”)—of six families were also shown to beMSH6-
variant carriers. Although the mutation status of the
mother of patient 1 has not been confirmed, she must
be a carrier, because she is a connecting link with patient
1. Four of the 12 families with truncating mutations
(table 4) fulfill the revised Amsterdam criteria. One of
the remaining eight families is a family with late-onset
CRC (i.e., in which the CRCs of the index patient and
two first-degree relatives in at least two successive gen-
erations were diagnosed at the age of 150 years). Two
of the 12 families with missense variants fulfill the re-
vised Amsterdam criteria (table 4). Ten of 15 carriers of
truncating mutations and 9 of 12 carriers of missense
variants had at least one first-degree relative, in most
cases a parent, with an HNPCC-related tumor (table 4).
The mean age at diagnosis (i.e., at the time of the first
cancer diagnosis) of CRC or endometrial cancer for all
MSH6-germline-variant carriers who have been proved
was 46 years for CRC and 52 years for endometrial
cancer (table 5). Of the 22 women known to be MSH6-
variant carriers, 9 had endometrial cancer, 1 had com-
plex atypical endometrial hyperplasia, and 1 had com-
plex non-atypical hyperplasia. Of only the 12 female
carriers of truncating mutations, 7 had endometrial can-
cer, and 1 had endometrial hyperplasia.
Localization of the CRCs and MSI Status
Of the 23 known MSH6-variant carriers (excluding
patient 15) with CRC, 14 (70%) had only a left-sided
CRC, 6 (30%) had only a right-sided CRC, and 3 had
both a left-sided and a right-sided CRC. Of the nine
right-sided CRCs, seven tumors were available for MSI
analysis, of which five, including four from truncating-
mutation carriers (table 2), showed an MSI-H pheno-
type. Of the 16 left-sided CRCs, 14 tumors were avail-
able, of which 6, including 4 from truncating-mutation
carriers and two from a missense-variant carrier, showed
an MSI-H phenotype.
Discussion
In this study, 25 index patients and 8 relatives with
MSH6 germline variants are presented. The molecular
and clinical data of these patients add to our under-
standing of the clinical implications of MSH6 germline
variants. However, new questions are raised concerning
the role individual variants may play in carcinogenesis
and concerning the mechanisms and the pathways that
Table 4
Family History of MSH6-Mutation Carriers
PATIENT
CANCERa [AGE AT DIAGNOSIS (YEARS)]
FAMILY
FEATURESbIndex Patient Parents Sibs/Children (Sex)
Second-Degree
Relatives
Third-Degree
Relatives (Sex)
Truncating mutation:
1 EC [46] EC [56] OC [35] EC [52], lung, skin OC [57], AD, CRC-L [37] (F), CRC AC(II)
2 CRC-L [41] BTC [82] lung/brain [69], CA, CA, CA CA
3 CRC-L [59], EC [65] CRC [74]/PRC [78] CRC-R [55] ST, BL, ST Late onset
4 CRC-L [46] CRC [41] CRC-L [47], AD [49] CRC [53], OC [50] AC
5 EC [50], CRC-R [50],
CRC-L [83], BRC [180]
Kidney EC [55], CRC-L [37] (M) BRC [35] AC(II)
6 CRC-R [45], CRC-L [53] GI [68] ST [49], EC/CX [50]
7 CRC-L [51], DUOD [51],
CAH [51]
Liver CRC-L [41], LEU Throat, CA
8 CRC-R [38] lung, lung, lung, lung BRC, NHL [57], PG [51]
9c Multiple tumors [77],
CRC-L [77]
BRC [49] LEU
10 CRC-R [55], CRC-L [55] CRC [42]/AD, BRC [58]
11 CRC-R [47] CRC [51, 69, and 79] ES [0] CRC [73/81], lung [54],
lung [56], EC [170]
CRC [40]/EC AC
12 OC [35], CRC-R [54] Liver [71]
Missense variant:
13 EC [45] CRC-L [49] (F)
14 CRC-L [48] CRC 78, CRC 76
15d EC [49] CRC-L [53] CRC [72], brain EC , CRC-L [32] (F) OC, neck AC(II)
16 CRC-L [63] CRC [63], PRC [73] PA [71]
17 CRC-R [43] BL [53] CRC [42], lung [62], CA [70]
18 CRC-R [37], CNAH [43] CRC 36 CRC CA, CA AC
19 CRC-L [42] CRC 41 CRC [81], CA [60] AC
20 CRC-R [36] CRC-R [79]/BRC [83],
lung [58]
AD-L[41], AD [46] CRC-L 52
21 CRC-L [36] CRC-L [40] (f), AD [42] KA, RCC
22 BRC [44], ST [64] CRC [48] CRC-L [49], AD-L[56]
23 AD-R [53] RCC [69] AD-L [58], AD [25] Liver, AD-L [64], CRC [60],
OC [39], CRC [40]
OC [37]
24 CRC-L [45] ST [150] CRC [!50]
25 EC/OC [46] ST, CRC [80], BRC [150]
a Underlining indicates histologically verified, boldface italic indicates carrier, and italic indicates not a carrier. CRCs are divided among left sided (CRC-L) and right sided (CRC-R); colorectal adenomas
(ADs) are divided among left sided (AD-L) and right sided (AD-R). BL p bladder cancer; BRC p breast cancer; BTC p biliary tract cancer; CA p cancer of unknown origin; CAH p complex atypical
hyperplasia; CNAH p complex non-atypical hyperplasia; CX p cervical cancer; DUOD p duodenal cancer; EC p endometrial cancer; ES p esophageal cancer; GI p gastrointestinal cancer; KA p Kahler
disease; LEU p leukemia; NHL p non-Hodgkin lymphoma; OC p ovarian cancer; PG p paraganglioma; PRC p prostate cancer; RCC p renal cell cancer; ST p stomach cancer.
b AC(II) p fulfilled (revised) Amsterdam criteria.
c This patient had multiple tumors (namely: OC, at age 49 years; sigmoid, at age 55 years; EC, at age 57 years; right renal pelvis, at age 63 years; left ureter, at age 64 years; BL, at age 65 years; basocellular
carcinoma, at age 75 years; ureter, at age 77 years; and two rectal carcinomas, at age 77 years).
d This patient also had an MLH1 truncating mutation.
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Table 5
Mean Age at Diagnosis of the First CRC or Endometrial Cancer—and Variety of Tumors—in MSH6–Germline-Mutation Carriers
TUMOR
FOUNDER-MUTATION
CARRIERS
TRUNCATING-MUTATION
CARRIERS
MISSENSE-MUTATION
CARRIERS ALL PATIENTS
Age [Range]
(years)
No. of
Patients
Age [Range]
(years)
No. of
Patients
Age [Range]
(years)
No. of
Patients
Age [Range]
(years)
No. of
Patients
CRC 45.8 [37–59] 8 47.3 [37–59] 13 44.7 [36–63] 11 46.1 [36–63] 24
EC 53.7 [46–65] 6 54.1 [46–65] 7 45.5 [45–46] 2 52.2 [45–65] 9
NOTE.—The patient with the additional frameshift MLH1 mutation was excluded.
are involved in carcinogenesis in patients harboring dif-
ferent variants, as found in this study.
In 316 apparently unrelated patients, five different
truncating germline mutations were detected in 12 pa-
tients. Haplotype analysis indicated a founder effect for
one mutation, which was shared by seven index pa-
tients, in exon 4a (650insT). In addition to the 5 trun-
cating mutations, another 10 different variants were
found in 13 patients. Several criteria can help to make
plausible that such a sequence variant has a pathogenic
nature (Hofstra et al. 1997; Cotton and Scriver 1998):
First, the variant should not be found in subjects with-
out the disease. None of the variants reported here oc-
curred in 200 control individuals. However, as most var-
iants were found in only 1 of the 316 patients, it cannot
be concluded from this that they are not rare polymor-
phisms without any clinical relevance.
Second, the variant causes functional loss of the gene
in a functional assay. This was previously shown for the
variant Ser144Ile, by Kolodner et al. (1999), in the Sac-
charomyces cerevisiae–based functional assay, indicating
that this is almost certainly a pathogenic mutation.
Third, the variant results in a substitution of amino
acids belonging to different polarity groups. This was
true for six of the missense variants. However, only two
of these, His1248Asp and Thr1219Ile, occurred in a
highly conserved region of the gene. This region shows
homology with the MutS gene in Escherichia coli and
codes for the COOH terminal region of the protein,
which contains four ATP-binding–site consensus se-
quences. Both variants are invariable between MSH6,
MSH2, and MutS (Palombo et al. 1995). For these two
variants, therefore, it is likely that they have an effect
on the proper function of the mutant protein and are
therefore considered as probably pathogenic. Whether
any of the other seven variants is pathogenic cannot be
substantiated at this moment, and these should be con-
sidered as having doubtful pathogenicity.
Twenty-seven patients came from families fulfilling
the original Amsterdam criteria for HNPCC (Vasen et
al. 1991). In 3 of these 27 families that fulfilled the
Amsterdam criteria, a probably pathogenic MSH6 mu-
tation was found. In addition, one missense variant of
doubtful pathogenicity was identified in the proband of
another family that fulfilled the Amsterdam criteria. In
the diagnostic setting, 17 other families that fulfilled the
Amsterdam criteria were previously found to harbor
truncating mutations in either MLH1 or MSH2 and
therefore were not analyzed for MSH6. Assuming that
no MSH6 germline mutations are present in these 17
families that fulfilled the Amsterdam criteria, our data
indicate that probably pathogenic MSH6 mutations oc-
cur at a lower frequency, 7% (3/44), than do MLH1 or
MSH2 mutations in these families, thus confirming pre-
vious reports (Park et al. 1999; Wang et al. 1999). Most
of the mutations that were found occurred in families
that were, according to our inclusion criteria, only sus-
pected to have HNPCC.
Our patients can be divided in three major groups:
(1) young patients with CRC (including those with mul-
tiple tumors for whom CRC was diagnosed at the age
of !50 years), (2) young patients with endometrial can-
cer (including those with multiple tumors for whom
endometrial cancer was diagnosed at the age of !50
years), and (3) patients with multiple tumors. Eight
(5%) of the 171 patients in the first group had a prob-
ably pathogenic MSH6 germline variant. This was 4%
(2/48) for patients in the second group and 13% (7/53)
for patients in the third group. In other, very small stud-
ies, the prevalence of truncatingMSH6mutations varied
from 0% to 20% in patients whose CRC was diagnosed
at the age of !50 years (Verma et al. 1999; Wang et al.
1999; Plaschke et al. 2000), whereas no MSH6 muta-
tions were found in 24 families with endometrial cancer
(Chadwick et al. 1999) and three probably pathogenic
missense MSH6 variants were found in 19 patients with
the combination of CRC and endometrial cancer (Char-
ames et al. 2001). When comparison of the prevalence
of MSH6 mutations with that of MLH1/MSH2 muta-
tions is made, among patients with CRC diagnosed at
the age of !50 years, the prevalence of the latter mu-
tations varied from 4% to 11% (Wijnen et al. 1998;
Montera et al. 2000; Salovaara et al. 2000; Berends et
al. 2001b). In studies of endometrial cancer, the prev-
alence of truncating MLH1 or MSH2 mutations varied
from 0% to 6% (Kobayashi et al. 1996; Kowalski et
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al. 1997; Berends et al. unpublished data). Among pa-
tients with multiple HNPCC-related tumor—mainly,
the combination of CRC and endometrial cancer—the
percentage of MLH1 and MSH2 carriers was 9%–54%
(Genuardi et al. 1999; Millar et al. 1999; Salovaara et
al. 2000; Berends et al., unpublished data). These data
show that, compared to mutations in MLH1 and in
MSH2, mutations in MSH6 may contribute, to an equal
extent, to the development, at an early age, of CRC and
endometrial cancer and to the development of multiple
tumors—in particular, CRC and endometrial cancer.
As we reported elsewhere (Wu et al. 1999), for a
smaller group of MSH6-mutation carriers from this
study population, a high proportion of CRC and of
endometrial cancers were MSI-L. This is in accordance
with studies in yeast, CRC cell lines, and MSH6 knock-
out mice showing that loss of MSH6 function caused
no or only weak repeat instability (Marsischky et al.
1996; Ku et al. 1999; Edelmann et al. 2000). An ex-
planation for this is that the major function of MSH6
is the correction of base-base mismatches and that these
do not give rise to MSI. On the basis of the function
of MSH6, it has been suggested that tumors from pa-
tients with an MSH6 germline mutation would more
often have unstable mononucleotide markers (Bhatta-
charyya et al. 1994; Papadopoulos et al. 1995; Verma
et al. 1999; Wijnen et al. 1999). However, instability
of dinucleotide markers was found just as frequently as
that of mononucleotide markers, in the tumors of our
patients. Substituting one of the three dinucleotide
markers in the set of five consensus markers with the
mononucleotide marker Bat40 would have caused a
change in the designation, to MSI-H, in only one en-
dometrial cancer (in patient 3). Somatic inactivation of
other MMR genes may have been involved in causing
the instability of the dinucleotide markers, and it has
been reported that MSH6 mutations in yeast and in an
endometrial cancer cell line in combination with so-
matic frameshift mutations in other genes (MLH1,
MSH2, MSH3) lead to an MSI-H phenotype (Marsisch-
ky et al. 1996; Risinger et al. 1996; Akiyama et al.
1997). Indeed, in our series, immunohistochemical anal-
ysis revealed the loss of MLH1 or MSH2 expression in
tumors from five patients, and four of these showed an
MSI-H phenotype. We did not examine the possible loss
of MSH3 function in the tumors.
The results with respect to the MSH6 staining in tu-
mors of MSH6-mutation carriers are largely in accor-
dance with the results of the mutation analysis. This is
similar to the results in CRCs and in endometrial cancers
of MLH1- and MSH2-mutation carriers (Leach et al.
1996; Thibodeau et al. 1996; Dietmaier et al. 1997; Ichi-
kawa et al. 1999; Marcus et al. 1999; Berends et al.
2001a). However, MSH6 staining was normal in some
of the tumors of truncating-mutation carriers. In two
patients with double tumors, the initial CRCs had a neg-
ative MSH6 staining, whereas the second tumor (an en-
dometrial cancer in patient 3 and a CRC in patient 10)
had a normal MSH6 staining. An explanation for this
discrepancy may be the absence of loss of heterozygosity,
as reported by Kruse et al. (2001) in a series of sebaceous
skin tumors in MSH2-mutation carriers. It may well also
be that in the tumors mentioned above, the wild-type
allele was not deleted but had a somatic mutation. This
may cause the production of an enzymatically inactive
but immunologically detectable protein. On the other
hand, the possiblilty that the MSI-L endometrial cancer
(in patient 3) and the MSI-H CRC (in patient 10) had
arisen independently and still had one normally func-
tioning MSH6 allele cannot be excluded.
Most of the missense variants did not lead to the loss
of MSH6 staining. This is not surprising in view of their
relatively small effect on the protein structure. On the
other hand, a missense variant may cause such a change
in the conformation that the protein cannot form a sta-
ble dimer with the MSH2 protein. This causes the un-
stable protein to be present only in low concentration,
owing to a short half-life time, and the antibody used
is thus not capable of recognizing the protein properly.
One could also speculate that, in addition to the wild-
type allele, the variant allele is mutated again by a sec-
ond hit and thus completely inactivated, causing loss of
protein expression.
As mentioned above, most of the families in which
we found MSH6 germline mutations were families that
were only suspected to have HNPCC. Unfortunately,
we have little data on segregation and penetrance of the
mutations. On the basis of the available information
about family history, the founder mutation, at least,
does not seem to have a low penetrance, since three of
the seven families with this mutation fulfilled the (re-
vised) Amsterdam criteria. Phenotypic analysis of these
seven families with the founder mutation did not reveal
a distinctive phenotype for this type of mutation. Al-
though the sample sizes were small, previous reports
suggest that the mean age at diagnosis of cancer in
MSH6-mutation carriers is somewhat higher than it is
in MLH1- and MSH2-mutation carriers (Miyaki et al.
1997; Kolodner et al. 1999; Wagner et al. 2001). In
families with either MLH1 or MSH2, the mean age at
diagnosis of CRC is 40–45 years, and the mean age at
diagnosis of endometrial cancer is 46–48 years (Vasen
et al. 1993; Watson et al. 1994). Since we included
predominantly patients with CRC or endometrial can-
cer diagnosed at the age of !50 years, we are not well
able to make any reliable statement about the age at
onset, in general, in MSH6-mutation carriers. In spite
of this bias, in the MSH6-truncating-mutation carriers
that we studied, the mean age at diagnosis of CRC is
47 years, and the mean age at diagnosis of endometrial
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cancer is 54 years. This is slightly higher than in MLH1-
and MSH2-mutation carriers, but, again, in general, the
age at onset may well be higher in the case of an MSH6
mutation. MSH6 germline mutations may be associated
with a high risk for endometrial cancer in female car-
riers. Eight (67%) of 12 proved female carriers of trun-
cating mutations had endometrial cancer or its precur-
sor, atypical hyperplasia. These results are comparable
with those reported by Wijnen et al. (1999), who found
a frequency of 73% in female carriers of MSH6 trun-
cating mutations. Although we have to deal with the
bias of the inclusion criterion used (i.e., criterion 1; see
Appendix A), the frequency of endometrial cancer in
MSH6-mutation carriers thus may be higher than that
in MLH1- and MSH2-mutation carriers, who have a
lifetime risk of 40%–50% for the development of en-
dometrial cancer.
A remarkable finding is that the majority of the CRCs
in the MSH6-variant carriers were located distally in
the colorectum. Thus far, when patients from the lit-
erature and from the population that we studied are
taken together, the location of 41 CRCs of MSH6-var-
iant carriers has been noted. Fourteen (34%) of these
CRCs were right-sided, and 27 (66%) were left-sided;
in three patients, both a left-sided and a right-sided CRC
occurred (Akiyama et al. 1997; Miyaki et al. 1997; Ko-
lodner et al. 1999; Planck et al. 1999; Shin et al. 1999;
Verma et al. 1999). This is in contrast with the situation
in MLH1- and MSH2-mutation carriers, in whom
∼70% of the CRCs were located proximal to the splenic
flexure. Such a differential preponderance of the site of
CRC development in patients with different mutated
genes may be a consequence of differences in the em-
bryologic origin of the proximal and distal colon, as
well as a consequence of their susceptibility to environ-
mental carcinogens, but a ready explanation is not at
hand.
As mentioned in the “Results” section, we divided
the MSH6 mutations among two groups: those with
truncating mutations (i.e., group A) and those with mis-
sense variants (i.e., group B). We wondered if, in ad-
dition to the data about change of amino acids and
conserved domains, other characteristics could help us
to clarify the possible pathogenicity of missense vari-
ants. First, between groups A and B, the proportions
(50% and 40%, respectively) of MSI-H CRCs and en-
dometrial cancers were not significantly different. Sec-
ond, clinical data may provide arguments for the path-
ogenicity of variants. Although we have few data about
segregation of the variants, 2 of 12 carriers in group B
(patient 15 excluded), compared to 4 of 12 in group A,
came from families that fulfilled the Amsterdam criteria.
Although the figures are small, the difference is not sta-
tistically significant. Furthermore, in 2 of the 10 families
that did not fulfill the Amsterdam criteria, an affected
sibling happened to be an MSH6-variant carrier. Most
patients had a parent with an HNPCC-related tumor.
No major difference, between patients in groups A and
B, in the frequency of affected parents existed. On the
other hand, in patients that fulfilled our inclusion cri-
teria (Appendix A) but did not have a variant in MSH6,
MLH1 or MSH2, only 96 (42%) of 228 had a first-
degree relative with an HNPCC-related tumor. Another
characteristic feature of HNPCC is the early age at di-
agnosis. The mean age at diagnosis of CRC or of en-
dometrial cancer for patients in group B was slightly
(but not significantly) lower—not higher—than that of
patients in group A. Finally, with respect to the site of
the CRC, either proximal or distal, there was no sig-
nificant difference between groups A and B. Taken to-
gether, the clinical data disclose a great resemblance
between the patients with missense variants and the pa-
tients with a truncating mutation, thereby supporting
the notion that these variants indeed may be pathogenic.
Segregation analysis could help to further elucidate this
issue. Also, functional assays will become important
tools in the identification of both the effects and the
clinical relevance of MSH6 variants.
In summary, this study has shown that the prevalence
of MSH6 mutations is ∼10% in classical families that
fulfill the Amsterdam criteria. In families that are only
suspected to have HNPCC, the prevalence of mutations
in MLH1 and in MSH2 and the prevalence of MSH6
variants is about the same. In MSH6-mutation carriers,
a substantial proportion of tumors are MSI-L, and CRCs
occur more frequently in the left colon than they do in
MLH1- or MSH2-mutation carriers. Female MSH6-mu-
tation carriers seem to be at a high risk for endometrial
cancer. Missense variants in MSH6 are about as common
as truncating mutations, and molecular and clinical char-
acteristics suggest that a considerable number of these
missense variants are pathogenic. Tumors from MSH6-
truncating-mutation carriers generally show no MSH6
staining, on immunohistochemical analysis; this is not
the case for tumors from carriers of a missense variant.
In conclusion, one should consider performingMSH6-
mutation analysis for all patients suspected of HNPCC.
Neither MSI nor immunohistochemistry should be a de-
finitive selection criterion for this mutation analysis.
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Appendix A
Inclusion Criteria for the Population-Based Study
Patients who fulfilled one of the following criteria
were included:
1. CRC or endometrial cancer was diagnosed at the age
of !50 years.
2. Patients either (a) had an HNPCC-related tumor (i.e.,
CRC; endometrial cancer; cancer of the small bowel,
the stomach, the pancreas, the biliary tract, or the
ovaries; or transitional cell cancer of the renal pelvis,
ureter, or bladder) and a first-degree relative with
CRC or endometrial cancer, one of which was di-
agnosed at the age of !50 years, or (b) had CRC or
endometrial cancer and a first-degree relative with an
HNPCC-related tumor, one of which was diagnosed
at the age of !50 years.
3. Patients had two or more HNPCC-related tumors,
irrespective of age at diagnosis.
4. Patients had a colorectal adenoma or atypical en-
dometrial hyperplasia and had a first-degree relative
with CRC or endometrial cancer, both of which were
diagnosed at the age of !50 years.
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